SLX-0953

N/A

Report date: 2023/11/07 14:45:59
NME

Base Information

Drug NameSLX-0953
Drug Alias NameSLX-0953
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMaternal embryonic leucine zipper kinase inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsMaternal embryonic leucine zipper kinaseTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiolexis Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiolexis Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A